CSPC Pharmaceutical Group Limited
CHJTF
$1.28
$0.0756.25%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 964.40M | 879.01M | 894.26M | 1.01B | 1.25B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 964.40M | 879.01M | 894.26M | 1.01B | 1.25B |
| Cost of Revenue | 317.53M | 279.37M | 289.32M | 295.85M | 346.45M |
| Gross Profit | 646.87M | 599.64M | 604.95M | 712.43M | 904.74M |
| SG&A Expenses | 259.68M | 310.92M | 292.65M | 292.46M | 458.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 756.23M | 772.53M | 768.84M | 777.88M | 967.91M |
| Operating Income | 208.17M | 106.48M | 125.43M | 230.41M | 283.28M |
| Income Before Tax | 246.92M | 115.83M | 131.92M | 240.68M | 286.69M |
| Income Tax Expenses | 41.42M | 41.32M | 26.97M | 44.37M | 59.66M |
| Earnings from Continuing Operations | 205.51M | 74.51M | 104.95M | 196.31M | 227.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -2.31M | 1.94M | 883.00K | -1.94M | -2.37M |
| Net Income | 203.20M | 76.46M | 105.84M | 194.37M | 224.65M |
| EBIT | 208.17M | 106.48M | 125.43M | 230.41M | 283.28M |
| EBITDA | 245.46M | 144.19M | 157.50M | 268.38M | 315.27M |
| EPS Basic | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| EPS Diluted | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 11.45B | 11.57B | 11.71B | 11.83B | 11.85B |
| Average Diluted Shares Outstanding | 11.45B | 11.57B | 11.71B | 11.83B | 11.85B |
| Dividend Per Share | -- | 0.01 | -- | 0.02 | -- |
| Payout Ratio | -- | -- | -- | -- | -- |